Endevica Bio

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Dragonfly Takes Back IL-12 Immunotherap

The confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. More than 70 executives and

Raising venture capital or launching an initial public offering in 2023 is nowhere near as easy as it was in the record-breaking VC funding and IPO days of 2020 and 2021, after a rough 2022 when fundr

Conditions look ripe for an uptick in M&A this year after a fairly quiet 2022, while other types of strategic deals are also expected to increase in the face of a challenging funding situation for bio